P
Pyxis Oncology, Inc. (PYXS)
NMS – Real Time Price. Currency in USD
3.18
+0.35 (12.37%)
At close: Aug 12, 2026, 4:00 PM EDT
3.15
-0.03 (-0.94%)
After-hours: Aug 12, 2026, 6:23 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
3.18
+0.35 (12.37%)
At close: Aug 12, 2026, 4:00 PM EDT
3.15
-0.03 (-0.94%)
After-hours: Aug 12, 2026, 6:23 PM EDT
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| Name | Position |
|---|---|
| Donna Regalado | Head of Human Resources |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer |
| Dr. Charles T. Gombar Ph.D. | Senior Vice President of Portfolio & Program Management |
| Dr. Hongwei Wang M.D., Ph.D. | Head of ADC Development & Clinical Strategy |
| Dr. Marsha Crochiere Ph.D. | Head of Translational Medicine & Research |
| Dr. Michael Bui | Senior Vice President of Global Regulatory Affairs |
| Dr. Shui He Ph.D. | Head of Biometrics |
| Dr. Supriya Roth Ph.D. | Head of Commercial Development |
| Mr. Jitendra Wadhane C.A., CPA | Chief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer |
| Mr. Thomas Civik | Interim CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-07-02 | 8-K | pyxs-20260630.htm |
| 2026-06-15 | 8-K | pyxs-20260615.htm |
| 2026-05-14 | 8-K | pyxs-20260514.htm |
| 2026-05-14 | 10-Q | pyxs-20260331.htm |
| 2026-04-30 | 8-K/A | pyxs-20260206.htm |
| 2026-03-23 | S-8 | pyxs-20260323.htm |
| 2026-03-23 | 8-K | pyxs-20260323.htm |
| 2026-03-23 | 10-K | pyxs-20251231.htm |
| 2026-02-06 | 8-K | pyxs-20260206.htm |
| 2025-12-18 | 8-K | pyxs-20251218.htm |